Targeting of the Myb-p300 Interaction in Myeloid Leukaemogenesis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1023175

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

MYB is a “cancer gene” which turns other genes on or off. MYB is needed by leukaemia cells but also for normal blood cell formation. This project aims to show that blocking interaction between the MYB protein and another protein called p300 is a promising strategy for leukaemia treatment, as leukaemia cells are more dependent on this interaction than normal cells. New molecules to block the MYB-p300 interaction will also be designed and tested; these may form a basis for new leukaemia drugs.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $625,980.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute myeloid leukaemia (AML) | cell transformation | drug development | mouse models | oncogenes | peptide inhibitors | transcription factor

Related Links